Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 61.1% in December

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 457,100 shares, a growth of 61.1% from the November 30th total of 283,800 shares. Based on an average daily trading volume, of 350,200 shares, the short-interest ratio is presently 1.3 days. Approximately 17.1% of the shares of the company are short sold.

Hedge Funds Weigh In On Aligos Therapeutics

An institutional investor recently raised its position in Aligos Therapeutics stock. Armistice Capital LLC grew its position in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 5.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,256,410 shares of the company’s stock after purchasing an additional 363,000 shares during the period. Armistice Capital LLC owned approximately 9.29% of Aligos Therapeutics worth $2,540,000 at the end of the most recent quarter. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Aligos Therapeutics Price Performance

Shares of NASDAQ ALGS opened at $41.15 on Friday. The stock has a market capitalization of $147.65 million, a PE ratio of -3.09 and a beta of 2.71. Aligos Therapeutics has a one year low of $6.76 and a one year high of $44.39. The business’s fifty day moving average price is $22.23 and its 200-day moving average price is $15.23.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing the consensus estimate of ($2.15) by ($0.92). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The business had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. During the same period last year, the business posted ($10.25) earnings per share. As a group, equities analysts expect that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).